Literature DB >> 20426665

Effect of a topical vasodilator on tumor hypoxia and tumor oxygen guided radiotherapy using EPR oximetry.

Huagang Hou1, Zrinka Abramovic, Jean P Lariviere, Marjeta Sentjurc, Harold Swartz, Nadeem Khan.   

Abstract

We sought to reduce tumor hypoxia by topical application of a vasodilator, benzyl nicotinate (BN), and investigated its effect on the growth of tumors irradiated at times when tumor pO(2) increased. EPR oximetry was used to follow the changes in the tissue pO(2) of subcutaneous radiation-induced fibrosarcoma (RIF-1) tumors during topical applications of 1.25-8% BN formulations for 5 consecutive days. The RIF-1 tumors were hypoxic with a tissue pO(2) of 4.6-7.0 mmHg. A significant increase in tumor pO(2) occurred 10-30 min after BN application. The formulation with the minimal BN concentration that produced a significant increase in tumor pO(2) was used for the radiation study. The tumors were irradiated (4 Gy x 5) at the time of the maximum increase in pO(2) observed with the 2.5% BN formulation. The tumors with an increase in pO(2) of greater than 2 mmHg from the baseline after application of BN on day 1 had a significant growth inhibition compared to the tumors with an increase in pO(2) of less than 2 mmHg. The results indicate that the irradiation of tumors at the time of an increase in pO(2) after the topical application of the 2.5% BN formulation led to a significant growth inhibition. EPR oximetry provided dynamic information on the changes in tumor pO(2), which could be used to identify responders and non-responders and schedule therapy during the experiments.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20426665      PMCID: PMC2877920          DOI: 10.1667/RR1947.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  48 in total

1.  ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.

Authors:  J Bernier; J Denekamp; A Rojas; M Trovò; J C Horiot; H Hamers; P Antognoni; O Dahl; P Richaud; J Kaanders; M van Glabbeke; M Piérart
Journal:  Radiother Oncol       Date:  1999-08       Impact factor: 6.280

2.  ARCON: accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the european organization for research and treatment of cancer (EORTC).

Authors:  J Bernier; J Denekamp; A Rojas; E Minatel; J Horiot; H Hamers; P Antognoni; O Dahl; P Richaud; M van Glabbeke; M Piérart
Journal:  Radiother Oncol       Date:  2000-05       Impact factor: 6.280

3.  Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide.

Authors:  J Bussink; J H Kaanders; A J Van der Kogel
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

4.  Hypoxia-induced tumour cell migration in an in vivo chicken model.

Authors:  L Plasswilm; A Tannapfel; N Cordes; R Demir; K Höper; J Bauer; J Höper
Journal:  Pathobiology       Date:  2000 May-Jun       Impact factor: 4.342

5.  Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes.

Authors:  J Bussink; J H Kaanders; A M Strik; A J van der Kogel
Journal:  Radiother Oncol       Date:  2000-10       Impact factor: 6.280

6.  Hypoxia and radiation therapy: past history, ongoing research, and future promise.

Authors:  Sara Rockwell; Iwona T Dobrucki; Eugene Y Kim; S Tucker Marrison; Van Thuc Vu
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 7.  Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.

Authors:  M Bache; M Kappler; H M Said; A Staab; D Vordermark
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Influence of nanosized delivery systems with benzyl nicotinate and penetration enhancers on skin oxygenation.

Authors:  Zrinka Abramović; Urska Sustarsic; Karmen Teskac; Marjeta Sentjurc; Julijana Kristl
Journal:  Int J Pharm       Date:  2008-03-22       Impact factor: 5.875

9.  Repeated tumor pO(2) measurements by multi-site EPR oximetry as a prognostic marker for enhanced therapeutic efficacy of fractionated radiotherapy.

Authors:  Huagang Hou; Jean P Lariviere; Eugene Demidenko; David Gladstone; Harold Swartz; Nadeem Khan
Journal:  Radiother Oncol       Date:  2008-11-14       Impact factor: 6.280

10.  Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors.

Authors:  Jérome Segers; Nathalie Crokart; Pierre Danhier; Vincent Grégoire; Bénédicte F Jordan; Bernard Gallez
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

View more
  9 in total

1.  Synergistic combination of hyperoxygenation and radiotherapy by repeated assessments of tumor pO2 with EPR oximetry.

Authors:  Huagang Hou; Ruhong Dong; Jean P Lariviere; Sriram P Mupparaju; Harold M Swartz; Nadeem Khan
Journal:  J Radiat Res       Date:  2011-07-29       Impact factor: 2.724

2.  Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.

Authors:  Sriram Mupparaju; Huagang Hou; Jean P Lariviere; Harold Swartz; Youssef Jounaidi; Nadeem Khan
Journal:  Oncol Rep       Date:  2011-04-15       Impact factor: 3.906

Review 3.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

4.  Assessment of the changes in 9L and C6 glioma pO2 by EPR oximetry as a prognostic indicator of differential response to radiotherapy.

Authors:  Huagang Hou; Sriram P Mupparaju; Jean P Lariviere; Sassan Hodge; Jiang Gui; Harold M Swartz; Nadeem Khan
Journal:  Radiat Res       Date:  2013-02-07       Impact factor: 2.841

5.  Application of Electron Paramagnetic Resonance (EPR) Oximetry to Monitor Oxygen in Wounds in Diabetic Models.

Authors:  Céline M Desmet; Aurore Lafosse; Sophie Vériter; Paolo E Porporato; Pierre Sonveaux; Denis Dufrane; Philippe Levêque; Bernard Gallez
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

6.  Temporal variation in the response of tumors to hyperoxia with breathing carbogen and oxygen.

Authors:  Hua-Gang Hou; Nadeem Khan; Gai-Xin Du; Sassan Hodge; Harold M Swartz
Journal:  Med Gas Res       Date:  2016-10-14

Review 7.  Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical Settings.

Authors:  Florence Colliez; Bernard Gallez; Bénédicte F Jordan
Journal:  Front Oncol       Date:  2017-01-25       Impact factor: 6.244

Review 8.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

Review 9.  Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.

Authors:  Jinsong Hu; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Karin Vanderkerken
Journal:  Dis Model Mech       Date:  2012-11       Impact factor: 5.758

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.